Webinar: Michael Gilhooley, Optogenetics
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
From our newsletters to the recordings of our webinars and everything in-between, use the filters (below) to find the content that's right for you.
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Inflammation and retinal degeneration in retinitis pigmentosa: Can lessons learned in the lab help us identify treatments in the clinic?
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
Elena Piotter, a PhD student working in Robert MacLaren’s group in the Nuffield Laboratory of Ophthalmology at the University of Oxford, is currently researching DNA and RNA base editing tools aiming to correct pathogenic mutations in ABCA4.